Uruguay
Diabetes country report 2000 — 2050
Skip Map
Number of adults (20–79 years) with diabetes in Uruguay (UY)
2000 | 98.5 thousand |
2011 | 148.6 thousand |
2024 | 201.5 thousand |
2050 | 234.5 thousand |
Uruguay is one of the 19 countries and territories in the IDF South and Central America Region.
Data source(s) used for the diabetes estimates in adults:
- Ministry of health, National health survey 2014 (2ª Encuesta Nacional de Factores de Riesgo de Enfermedades No Transmisibles)
2000
2011
2024
2050
Loading...
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | 98.5 | 148.6 | 201.5 | 234.5 |
Age-standardised prevalence of diabetes, % | - | 5.7 | 7.8 | 8.7 |
Proportion of people with undiagnosed diabetes, % | - | - | 48.9 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 98.5 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 122.0 | 133.1 |
Age-standardised prevalence of IFG, % | - | - | 4.9 | 5.2 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 153.3 | 301.5 | 332.7 |
Age-standardised prevalence of IGT, % | - | 6.2 | 12.1 | 12.8 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 1,060.0 | 1,269.7 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 7.6 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | - | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | - | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | - | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | - | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 308.2 | 309.1 |
Total diabetes-related health expenditure, ID million | - | - | 420.5 | 421.7 |
Diabetes-related health expenditure per person, USD | - | 927.0 | 1,529.8 | 1,318.2 |
Diabetes-related health expenditure per person, ID | - | - | 2,087.1 | 1,798.5 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 3,113.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 597.1 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | 2,166.0 | 2,237.1 | 2,394.7 | 2,436.6 |
Population of children and adolescents (0-19 y) | - | - | 854,002.5 | - |
Loading...
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | 98.5 |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | 2,166.0 |
Population of children and adolescents (0-19 y) | - |